Close menu




December 15th, 2020 | 14:46 CET

TeamViewer, Dermapharm, Q&M Dental Group: Deciding tomorrow's profits!

  • Investments
Photo credits: Q & M Dental Group

When it became apparent in March that millions of employees would suddenly be working from home offices, the market initially focused on the obvious solutions. TeamViewer is a software that many users were already familiar with at the time, allowing them to access PCs remotely. Particularly for people who had previously worked exclusively in the office, the software, some of which was free, was a good solution. But the world keeps turning. In the meantime, many companies have made the switch, offering their employees VPN access to the company network or using other cloud solutions. It is also likely that one or two mobile devices have been distributed to employees in recent months, at least according to sales in the hardware sector.

time to read: 2 minutes | Author: Nico Popp
ISIN: SG2E73981531 , DE000A2YN900 , DE000A2GS5D8

Table of contents:


    TeamViewer: What will become of the lockdown stock of the first hour?

    Consequently, the initial euphoria surrounding TeamViewer has quickly subsided. On a one-year view, however, a share price gain of around 34% remains. Most recently, the market has focused more and more on the competition: In addition to all the large tech companies, smaller companies from all over the world are also looking to TeamViewer's market share. To survive in such a situation can be difficult. The Company is represented worldwide and has invested heavily in sales.

    It is even represented in India, China and Singapore. In the USA, the Company also wants to target customers and win them over to its subscription model. Since peaking at more than EUR 35 in the summer, the share price has fallen and is in a negative trend. Given the general market environment, the share is no longer likely to be engaging in the weeks ahead - even despite the new lockdown.

    Dermapharm as a long-term beneficiary?

    Dermapharm's share price has risen by 37% in the past twelve months. However, there was little sign of this recently - the value consolidated somewhat. The share had become known to more and more investors in recent months because Dermapharm cooperates with BioNTech and makes capacities available to the vaccine manufacturer. Dermapharm specializes in vitamins, enzymes and other products. Among other things, the Munich suburbanites extract active ingredients from plants and are also involved in the field of cannabis products.

    In the wake of the pandemic and increased awareness of issues such as health and the immune system, Companies like Dermapharm could benefit in the long term. Most recently, the Company raised its forecast, expecting up to 15% more sales in 2020. As a result, the Company also increased its dividend and offers about a 2% dividend yield. Since Dermapharm's stock market debut in 2018, the value has climbed continuously. Even the crisis only caused short-term uncertainty. In the long term, the title appears promising.

    Q&M Dental Group: clinic chain with Covid-19 boost

    A Company that is still largely unknown in Germany is the Q&M Dental Group. Q&M owns eighty medical facilities in Singapore, including mainly dental clinics, making it the island's largest private provider. When demand for dental treatment collapsed at short notice in the wake of the first wave of the pandemic, Q&M Dental reacted immediately and relied on a sophisticated testing strategy.

    In April, the Company acquired a stake in the medical technology Company Acumen Diagnostics. Among other things, this Company manufactures test kits for Covid-19 and has also been supplying Q&M since then. As a positive side effect, the increased demand for tests is making a positive contribution to Q&M's figures. However, the Company emphasizes that the traditional medical treatment business remains the Company's mainstay and is expected to account for 90% of sales.

    Q&M as a bet on the rise of the Asian middle class

    Analysts at KGI, an Asian analyst firm, see a potential upside of SGD 0.54 for the stock, or about twenty percent more than the current price of SGD 0.47. As a comprehensive testing strategy is expected to be important even despite vaccines, Q&M's business could benefit from its stake in Acumen into 2022, they said. In its core business, the Company plans to expand into other regions of Asia, allowing Q&M to benefit from the growing prosperity in Asia. The middle class, in particular, is developing dynamically there and is increasingly demanding medical and aesthetic services in addition to consumer goods.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by André Will-Laudien on January 31st, 2023 | 14:50 CET

    E-mobility 2023: The Tesla hunters are coming! BYD, Lucid Motors, Tocvan Ventures. Will the Varta share now also fly?

    • Mining
    • Gold
    • Electromobility
    • Investments

    It Is hard to believe! The Tesla share is once again making a name for itself. Analysts went into the presentation of the annual figures with cautious expectations because there were many negative rumors surrounding Elon Musk's electronics company: Fewer sales? Cars on stockpile? Again, it came as no one had expected it. Elon Musk delivered and simultaneously mocked all the shorties who wanted to push his stock below USD 100 at the turn of the year. This gambit went badly wrong because Tesla was able to deliver even better figures than expected, and there was no stopping the share. With plus 70% in only 4 weeks, the Tesla share belongs to the shooting stars since the turn of the year - the short sellers must have lost their desire completely. But the variety of interesting shares is significant. Where are the opportunities for e-investors lurking?

    Read

    Commented by Nico Popp on January 31st, 2023 | 14:33 CET

    This new project changes everything: Deutsche Bank, Aspermont, Alibaba

    • Digitization
    • Innovations
    • Technology
    • Investments

    When processes go digital, great opportunities arise: automation and scaling can ensure growth and turn established business models into high-flyers. But which companies should investors actively support in their transformation? Where is there real potential for investors, and where are companies just spreading buzzwords? We highlight three stocks for you.

    Read

    Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

    Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

    • Biotechnology
    • Cancer
    • Covid19
    • Investments

    Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

    Read